Dengue Therapeutics, Chemoprophylaxis, and Allied Tools

State of the Art and Future Directions

James Whitehorn, Sophie Yacoub, Katherine L. Anders, Louis R. Macareo, M. Cristina Cassetti, Vinh Chau Nguyen Van, Pei-Yong Shi, Bridget Wills, Cameron P. Simmons

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic intervention that reduces the duration and severity of dengue symptoms and diminishes the likelihood of severe complications. To this end, there are active discovery efforts in industry and academia to develop interventions, with a focus on small molecule inhibitors of dengue virus replication that are suitable for therapy or chemoprophylaxis. Advancements in animal models of dengue virus infection together with the possibility of a dengue human infection model have further enhanced the platform for dengue drug discovery. Whilst drug discovery efforts gestate, there are ongoing clinical research designed to benefit today's patients, including trials of supportive care interventions, and descriptive studies that should improve the ability of clinicians to make an accurate diagnosis early in the illness course and to identify patients most at risk of progression to severe disease. This review provides a state of the art summary of dengue drug discovery, clinical trials, and supportive allied research and reflects discussions at the 2nd International Dengue Therapeutics Workshop held in Ho Chi Minh City, Vietnam, in December 2013.

Original languageEnglish (US)
Article numbere3025
JournalPLoS Neglected Tropical Diseases
Volume8
Issue number8
DOIs
StatePublished - Aug 28 2014
Externally publishedYes

Fingerprint

Dengue
Chemoprevention
Drug Discovery
Dengue Virus
Therapeutics
Vietnam
Virus Diseases
Virus Replication
Research
Direction compound
Industry
Animal Models
Clinical Trials
Education
Infection

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Whitehorn, J., Yacoub, S., Anders, K. L., Macareo, L. R., Cassetti, M. C., Nguyen Van, V. C., ... Simmons, C. P. (2014). Dengue Therapeutics, Chemoprophylaxis, and Allied Tools: State of the Art and Future Directions. PLoS Neglected Tropical Diseases, 8(8), [e3025]. https://doi.org/10.1371/journal.pntd.0003025

Dengue Therapeutics, Chemoprophylaxis, and Allied Tools : State of the Art and Future Directions. / Whitehorn, James; Yacoub, Sophie; Anders, Katherine L.; Macareo, Louis R.; Cassetti, M. Cristina; Nguyen Van, Vinh Chau; Shi, Pei-Yong; Wills, Bridget; Simmons, Cameron P.

In: PLoS Neglected Tropical Diseases, Vol. 8, No. 8, e3025, 28.08.2014.

Research output: Contribution to journalArticle

Whitehorn, J, Yacoub, S, Anders, KL, Macareo, LR, Cassetti, MC, Nguyen Van, VC, Shi, P-Y, Wills, B & Simmons, CP 2014, 'Dengue Therapeutics, Chemoprophylaxis, and Allied Tools: State of the Art and Future Directions', PLoS Neglected Tropical Diseases, vol. 8, no. 8, e3025. https://doi.org/10.1371/journal.pntd.0003025
Whitehorn, James ; Yacoub, Sophie ; Anders, Katherine L. ; Macareo, Louis R. ; Cassetti, M. Cristina ; Nguyen Van, Vinh Chau ; Shi, Pei-Yong ; Wills, Bridget ; Simmons, Cameron P. / Dengue Therapeutics, Chemoprophylaxis, and Allied Tools : State of the Art and Future Directions. In: PLoS Neglected Tropical Diseases. 2014 ; Vol. 8, No. 8.
@article{9fd8848c7c4d4362980f2a4c8bae3899,
title = "Dengue Therapeutics, Chemoprophylaxis, and Allied Tools: State of the Art and Future Directions",
abstract = "Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic intervention that reduces the duration and severity of dengue symptoms and diminishes the likelihood of severe complications. To this end, there are active discovery efforts in industry and academia to develop interventions, with a focus on small molecule inhibitors of dengue virus replication that are suitable for therapy or chemoprophylaxis. Advancements in animal models of dengue virus infection together with the possibility of a dengue human infection model have further enhanced the platform for dengue drug discovery. Whilst drug discovery efforts gestate, there are ongoing clinical research designed to benefit today's patients, including trials of supportive care interventions, and descriptive studies that should improve the ability of clinicians to make an accurate diagnosis early in the illness course and to identify patients most at risk of progression to severe disease. This review provides a state of the art summary of dengue drug discovery, clinical trials, and supportive allied research and reflects discussions at the 2nd International Dengue Therapeutics Workshop held in Ho Chi Minh City, Vietnam, in December 2013.",
author = "James Whitehorn and Sophie Yacoub and Anders, {Katherine L.} and Macareo, {Louis R.} and Cassetti, {M. Cristina} and {Nguyen Van}, {Vinh Chau} and Pei-Yong Shi and Bridget Wills and Simmons, {Cameron P.}",
year = "2014",
month = "8",
day = "28",
doi = "10.1371/journal.pntd.0003025",
language = "English (US)",
volume = "8",
journal = "PLoS Neglected Tropical Diseases",
issn = "1935-2727",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Dengue Therapeutics, Chemoprophylaxis, and Allied Tools

T2 - State of the Art and Future Directions

AU - Whitehorn, James

AU - Yacoub, Sophie

AU - Anders, Katherine L.

AU - Macareo, Louis R.

AU - Cassetti, M. Cristina

AU - Nguyen Van, Vinh Chau

AU - Shi, Pei-Yong

AU - Wills, Bridget

AU - Simmons, Cameron P.

PY - 2014/8/28

Y1 - 2014/8/28

N2 - Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic intervention that reduces the duration and severity of dengue symptoms and diminishes the likelihood of severe complications. To this end, there are active discovery efforts in industry and academia to develop interventions, with a focus on small molecule inhibitors of dengue virus replication that are suitable for therapy or chemoprophylaxis. Advancements in animal models of dengue virus infection together with the possibility of a dengue human infection model have further enhanced the platform for dengue drug discovery. Whilst drug discovery efforts gestate, there are ongoing clinical research designed to benefit today's patients, including trials of supportive care interventions, and descriptive studies that should improve the ability of clinicians to make an accurate diagnosis early in the illness course and to identify patients most at risk of progression to severe disease. This review provides a state of the art summary of dengue drug discovery, clinical trials, and supportive allied research and reflects discussions at the 2nd International Dengue Therapeutics Workshop held in Ho Chi Minh City, Vietnam, in December 2013.

AB - Dengue is the most common arboviral disease of humans. There is an unmet need for a therapeutic intervention that reduces the duration and severity of dengue symptoms and diminishes the likelihood of severe complications. To this end, there are active discovery efforts in industry and academia to develop interventions, with a focus on small molecule inhibitors of dengue virus replication that are suitable for therapy or chemoprophylaxis. Advancements in animal models of dengue virus infection together with the possibility of a dengue human infection model have further enhanced the platform for dengue drug discovery. Whilst drug discovery efforts gestate, there are ongoing clinical research designed to benefit today's patients, including trials of supportive care interventions, and descriptive studies that should improve the ability of clinicians to make an accurate diagnosis early in the illness course and to identify patients most at risk of progression to severe disease. This review provides a state of the art summary of dengue drug discovery, clinical trials, and supportive allied research and reflects discussions at the 2nd International Dengue Therapeutics Workshop held in Ho Chi Minh City, Vietnam, in December 2013.

UR - http://www.scopus.com/inward/record.url?scp=84911911695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911911695&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0003025

DO - 10.1371/journal.pntd.0003025

M3 - Article

VL - 8

JO - PLoS Neglected Tropical Diseases

JF - PLoS Neglected Tropical Diseases

SN - 1935-2727

IS - 8

M1 - e3025

ER -